Have the major cardiovascular outcomes trials impacted payer approval rates for PCSK9 inhibitors?

Ann Marie Navar; Hillary M. Mulder; Daniel M. Wojdyla; Eric D. Peterson

doi:10.1161/CIRCOUTCOMES.119.006019

Have the major cardiovascular outcomes trials impacted payer approval rates for PCSK9 inhibitors?

Ann Marie Navar, Hillary M. Mulder, Daniel M. Wojdyla, Eric D. Peterson

Research output: Contribution to journal › Article › peer-review

Original language	English (US)
Article number	e006019
Journal	Circulation: Cardiovascular Quality and Outcomes
DOIs	https://doi.org/10.1161/CIRCOUTCOMES.119.006019
State	Accepted/In press - 2020
Externally published	Yes

Keywords

Approval rates
PCSK9
Utilization

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1161/CIRCOUTCOMES.119.006019

Cite this

@article{5398e40452504f8fa0f2ffe2d8c947d8,

title = "Have the major cardiovascular outcomes trials impacted payer approval rates for PCSK9 inhibitors?",

keywords = "Approval rates, PCSK9, Utilization",

author = "Navar, {Ann Marie} and Mulder, {Hillary M.} and Wojdyla, {Daniel M.} and Peterson, {Eric D.}",

year = "2020",

doi = "10.1161/CIRCOUTCOMES.119.006019",

language = "English (US)",

journal = "Circulation: Cardiovascular Quality and Outcomes",